Introduction
============

The family of large clostridial glucosylating toxins (LCGTs) encompasses toxin A (TcdA) and toxin B (TcdB) of *Clostridioides difficile*, lethal toxin (TcsL) and hemorrhagic toxin (TcsH) from *Clostridium sordellii*, and large toxin (TpeL) from *C. perfringens* ([@B31]; [@B10]; [@B11]; [@B17]). These toxins exhibit molecular masses ranging from 191 to 307 kDa and an AB-like domain structure with a N-terminal glucosyltransferase domain and a C-terminal delivery domain. Upon cell entry by receptor-mediated endocytosis, the LCGTs mono-O-glucosylate Rho/Ras subfamily GTPases ([@B6]; [@B12]). Rho and Ras subtype proteins are key regulators of cytoskeletal dynamics, cell proliferation, and cell death/survival. Mono-O-glucosylation of RhoA at Thr-37 or of Rac/Cdc42 and (H/K/N)Ras at equivalent Thr-35 renders cellular Rho/Ras proteins inactive, resulting in a breakdown of the actin cytoskeleton, inhibition of cell proliferation, and cell death ([@B5]; [@B22]; [@B7]; [@B24]; [@B39]). The glucosylating toxins are regarded to be responsible for the loss of intestinal barrier function and for inflammation observed in *C. difficile*-associated diarrhea (CDAD), *C. sordellii*-induced haemorrhagic enteritis and enterotoxemia, and *C. perfringens*-associated necrotic enteritis ([@B29]; [@B33]).

In cultured cells, TcdA and TcdB trigger inflammasome activation with caspase-1 activation, based on the recognition of RhoA glucosylation by pyrin ([@B25]; [@B40]). Caspase-1 subsequently activates IL-1β and IL-18, which in turn induce the release of IL-6, IFN-γ, and IL-8. Either of these proinflammatory responses is positively regulated by Ras-GTPases ([@B34]; [@B18]), which leads to the hypothesis that Ras glucosylation by glucosylating toxins results in (at least) reduced proinflammatory responses. Some observations support this hypothesis, as TcdB (not the Ras glucosylating TcdA) has been suggested to be primarily responsible for inflammatory responses in CDI ([@B2]; [@B30]). Against this background, data on Ras glucosylation are required to estimate the proinflammatory effects of the toxins. A quantitative evaluation of the GTPase substrate profiles glucosylated in cells treated with TcdB (as well as with the related TcsL) is not yet available. Therefore, the profiles of substrate GTPases glucosylated by TcdB, TcsL, and TcdA were evaluated in toxin-treated Caco-2 cells using multiple reaction monitoring (MRM) mass spectrometry. MRM analysis allows the quantification of the glucosylation of small GTPases in cultured cells ([@B19]). This study provides evidence on the glucosylation of (H/K/N)Ras and Rap(1/2) by TcsL and TcdA. In contrast, neither TcdB isoform tested glucosylated (H/K/N)Ras and Rap(1/2). Furthermore, the glucosylation of (H/K/N)Ras was detected in TcdA-treated cells, as analyzed exploiting the glucosylation-sensitive Ras(Mab 27H5) antibody ([@B16]). Finally, \[^14^C\]glucosylation of (H/K/N)Ras by TcdA was found in a cell-free system complemented with Caco-2 lysates.

Results
=======

TcdA-Catalyzed Glucosylation of Ras Subtype GTPases in Cultured Cells
---------------------------------------------------------------------

The *C. difficile* strain VPI10463 \[isolated from an abdominal wound, ([@B35])\] has long been regarded as a reference strain. *C. difficile* strain VPI10463 exhibits an A+B+CDT- toxinotype i.e., it produces TcdA-10463 and TcdB-10463 but not the binary *C. difficile* toxin (CDT) ([@B8]). To evaluate possible differences in the GTPase substrate profiles of TcdA-10463 and TcdB-10463, Caco-2 cells were treated with the toxins and GTPase substrate profiles were analyzed in terms of the MRM method. Treatment of Caco-2 cells with TcdB-10463 resulted in time-dependent mono-O-glucosylation of the Rho subtype GTPases Rho(A/B/C), Rac1, RhoG, and Cdc42 (Figure [1A](#F1){ref-type="fig"}). Remarkably, neither Rap(1/2) nor (H/K/N)Ras were glucosylated (Figure [1A](#F1){ref-type="fig"}). Furthermore, TcdB-10463-catalyzed glucosylation of Rap(1/2) or (H/K/N)Ras was observed neither upon treatment with an about three orders of magnitude higher TcdB-10463 concentration of 2 nM (Figure [1B](#F1){ref-type="fig"}) nor upon prolonged TcdB-10463 treatment for 48h (Figure [1G](#F1){ref-type="fig"}). TcdA-10463 glucosylated Rap(1/2) and (less efficaciously) (H/K/N)Ras as well as its canonical Rho subfamily substrate GTPases including Rho(A/B/C), Rac1, RhoG, and Cdc42 (Figures [1D,E](#F1){ref-type="fig"}). The latter observations were consistent with published data ([@B19]). Combined treatment of Caco-2 cells with TcdA (300 pM) and TcdB (3 pM) resulted in glucosylation kinetics almost similar to that of TcdA (300 pM) alone, excluding synergistic effects in the kinetics of substrate GTPase glucosylation upon combined toxin treatment. The only exception was (H/K/N)Ras, which glucosylation seemed to suppressed upon combined treatment with TcdA and TcdB (Figures [1D,F](#F1){ref-type="fig"}). The latter observation suggests that TcdB suppressed TcdA-catalyzed Ras glucosylation.

![Mass spectrometry-based evaluation of the substrate GTPase profiles glucosylated by LCGTs. Caco-2 cells were exposed to recombinantly prepared TcdB-10463 **(A,B,F,G)**, to TcsL prepared from *C. sordellii* strain 6018 (TcsL-6018) **(C)**, recombinantly prepared TcdA-10463 **(D--F)**, and recombinantly prepared TcdB-20291 **(H)**. Upon cell lysis, small GTPases of the Rho and Ras subfamilies were analyzed for cellular concentrations of glucosylated GTPases using MRM analysis. Glucosylation was given as the ratio of the concentration of glucosylated GTPase per concentration of total GTPase. All experiments were conducted with three biological replicates. The error bars are representing the SD of the mean.](fmicb-09-03078-g001){#F1}

Next, the substrate GTPase profile of TcdB from the hypervirulent, toxinotype A+B+CDT+ *C. difficile* strain R20291 (isolated from the feces of a symptomatic patient in United Kingdom) was evaluated upon prolonged treatment of Caco-2 cells for 48 h. TcdB-R20291 specifically glucosylated Rho/Rac/Cdc42 subtype GTPases (but not Ras subtype GTPases) (Figure [1H](#F1){ref-type="fig"}). TcdB-R20291 and TcdB-10463 thus exhibited a similar substrate GTPase profile, with the Ras subtype GTPases Rap(1/2) and (H/K/N)Ras not being glucosylated (Figures [1G,H](#F1){ref-type="fig"}).

Among the family of glucosylating toxins, *C. sordellii* lethal toxin (TcsL) has been classified as the prototype of Ras glucosylating toxin ([@B10]; [@B11]). This notion was re-confirmed using MRM analysis of TcsL-treated Caco-2 cells: Ras subtype GTPases Rap(1/2) and (H/K/N)Ras were the preferred cellular substrates of the related TcsL: (H/K/N)Ras, Rac1, Rap(1/2) \> RhoG \> \> Rho(A/B/C) (Figure [1C](#F1){ref-type="fig"}). Weak glucosylation of Rho(A/B/C) (not observed until TcsL treatment for 24 h) was background (Figure [1C](#F1){ref-type="fig"}). In contrast to TcdA/TcdB-treated Caco-2 cells, Cdc42 was not read from TcsL-treated Caco-2 cells, which might due to Cdc42 degradation (Figure [1C](#F1){ref-type="fig"}).

Immunoblot analysis exploiting the Rac1(Mab 102) and the Ras(Mab 27H5) antibodies have evolved into a routine method for tracking mono-O-glucosylation of cellular Rac/Cdc42 and (H/K/N)Ras, respectively ([@B9]; [@B16]; [@B1]). Once Rac/Cdc42 or (H/K/N)Ras is mono-O-glucosylated, the antibodies do not detect their epitopes, resulting in signal loss. In contrast, the H-Ras (C20) and the Rac1 (Mab 23A8) antibodies are glucosylation insensitive and can be used to quantify total levels of H-Ras or Rac1, respectively. TcdA-10463-treated Caco-2 cells exhibited time-dependent glucosylation of (H/K/N)Ras with about 50% of total (H/K/N)Ras being glucosylated after 12 h (Figures [2A,B](#F2){ref-type="fig"}). Detection of exemplarily H-Ras using the H-Ras(C20) antibody showed no decrease, indicating that the cellular level of H-Ras was not changed upon TcdA treatment (Figure [2A](#F2){ref-type="fig"}). In contrast to (H/K/N)Ras, TcdA-10463-catalyzed glucosylation of Rac/Cdc42 was almost complete upon 3 h of TcdA treatment, as evaluated using the Rac1(clone 102) antibody (Figures [2A,B](#F2){ref-type="fig"}). The cellular level of Rac1 was not changed as analyzed using the Rac1(Mab 23A8) antibody, confirming that decreasing detection by the Rac1(Mab 102) antibody was due to glucosylation but not due to degradation (Figure [2A](#F2){ref-type="fig"}). In TcdB-10463-treated Caco-2 cells, rapid glucosylation of Rac/Cdc42 but not of (H/K/N)Ras was detected exploiting the Rac1(Mab 102) and the Ras(Mab 27H5) antibodies (Figure [2C](#F2){ref-type="fig"}). Taken together, (i) either MRM analysis or immunoblot analysis comparably tracked Rac/Cdc42 and (H/K/N)Ras glucosylation in toxin-treated Caco-2 cells, (ii) the glucosylation of (H/K/N)Ras by TcdA-10463 was delayed as compared with glucosylation of Rac/Cdc42 glucosylation, and (iii) (H/K/N)Ras was not glucosylated by TcdB-10463.

![Immunoblot-based analysis of the glucosylation of (H/K/N)Ras and Rac/Cdc42 in TcdA- and TcdB-treated Caco-2 cells. Caco-2 cells were exposed to natively prepared TcdA-10463 **(A,B)** or TcdB-10463 **(C,D)** for the indicated times. Upon cell lysis, the cellular concentrations of glucosylated (H/K/N)Ras and Rac/Cdc42 subtype GTPases were evaluated using immunoblot analysis. Immunoblots were quantified using Kodak software. The amounts of non-glucosylated Rac/Cdc42 and non-glucosylated (H/K/N)Ras relative to the respective total levels of Rac1 and H-Ras are expressed as mean ± SD of three experiments.](fmicb-09-03078-g002){#F2}

The kinetics of Rac/Cdc42 and (H/K/N)Ras glucosylation were further investigated in African green monkey kidney (Vero) cells, an epithelial cell line with high sensitivity to the *C. difficile* toxins ([@B27]). In TcdA-10463-treated Vero cells, Rac/Cdc42 was about one order magnitude more efficaciously glucosylated than (H/K/N)Ras, as evaluated exploiting the Rac1(Mab 102) and the Ras(Mab 27H5) antibodies (Figures [3A,B](#F3){ref-type="fig"}). In contrast to Caco-2 cells, (H/K/N)Ras was completely glucosylated in TcdA-10463-treated Vero cells (Figures [3A,B](#F3){ref-type="fig"}). In TcdB-10463-treated Vero cells, (H/K/N)Ras was not glucosylated even at TcdB-10463 concentrations two orders of magnitude greater than those required for complete Rac/Cdc42 glucosylation (Figures [3C,D](#F3){ref-type="fig"}). These observation from Vero cells further excluded that (H/K/N)Ras was glucosylated by TcdB-10463.

![Immunoblot-based analysis of the glucosylation of (H/K/N)Ras and Rac/Cdc42 in TcdA- and TcdB-treated Vero cells. Vero cells were exposed to the indicated concentrations of native TcdA-10463 **(A,B)** and TcdB-10463 **(C,D)** for 16 h. The cellular levels of non-glucosylated (H/K/N)Ras, total H-Ras, non-glucosylated Rac/Cdc42, total Rac1, and beta-actin were analyzed by immunoblot analysis. Immunoblots were quantified using Kodak software. The amounts of non-glucosylated Rac/Cdc42 and non-glucosylated (H/K/N)Ras relative to the, respectively, levels of Rac1 and H-Ras are expressed as mean ± SD of three experiments.](fmicb-09-03078-g003){#F3}

The cellular levels of active GTP-bound Ras were next analyzed using pull-down assay exploiting the Ras binding domain of Raf kinase ([@B36]). In TcdA-10463-treated Vero cells, (H/K/N)Ras was completely inactivated, as no GTP-bound active (H/K/N)Ras was detected (Figure [4](#F4){ref-type="fig"}). In contrast, GTP-bound active (H/K/N)Ras was present in TcdB- and mock-treated cells (Figure [4](#F4){ref-type="fig"}). (H/K/N)Ras activates the canonical pathways leading to activation of p44/42-MAP kinase (ERK1/2). In mock-treated Vero cells, active ERK1/2 was detected in terms of the cellular level of pT202/Y204-ERK1/2. In TcdA-10463-treated Vero cells, almost no pT202/Y204-ERK1/2 was detected (Figure [4](#F4){ref-type="fig"}), reflecting Ras inactivation. The level of pT202/Y204-ERK1/2 was slightly reduced in TcdB-10463-treated cells (as compared to mock-treated cells) (Figure [4](#F4){ref-type="fig"}). This observation reflects that -- besides (H/K/N)Ras -- ERK1/2 is activated by Rac1 to some extent ([@B26]). Slightly reduced levels of pERK1/2 in TcdB-treated Vero cells most likely reflected TcdB-catalyzed Rac1 glucosylation. The Ras-ERK pathway was thus completely inhibited in TcdA-treated Vero cells, reinforcing the view that (H/K/N)Ras was inactivated by TcdA.

![Inactivation of (H/K/N)Ras in TcdA-treated Vero cells. Vero cells were exposed to native TcdA-10463 and TcdB-10463 for 16 h. Cells were lysed and objected to effector pull-down assay exploiting the Ras-binding domain of Raf kinase. The cellular levels of GTP-loaded (H/K/N)Ras, total H-Ras, pT202/pY204-p44/42-MAP kinase (pT202/pY204-ERK1/2), and total p44/42-MAP kinase (ERK1/2) were analyzed by immunoblot analysis using the indicated antibodies.](fmicb-09-03078-g004){#F4}

Enhanced Glucosylation of Substrate GTPases in the Presence of Caco-2 Lysates
-----------------------------------------------------------------------------

Next, GTPase glucosylation catalyzed by the recombinant glucosyltransferase domains of TcdA-10463 (rN-TcdA) and of TcdB-10463 (rN-TcdB) was re-analyzed in a cell-free system. Specifically GST-Rac1 but not GST-H-Ras was \[^14^C\]glucosylated by rN-TcdA and rN-TcdB applied at a relatively low toxin concentration of 0.3 nM (Figure [5A](#F5){ref-type="fig"}). In the presence of Caco-2 lysates (that contain the heavy and light membrane fractions), Rac1 glucosylation by rN-TcdA was strongly enhanced (Figures [5A,B](#F5){ref-type="fig"}). Furthermore, partial glucosylation of (H/K/N)Ras by rN-TcdA was observed in the presence of Caco-2 lysates (Figures [5A,B](#F5){ref-type="fig"}). Rac1 glucosylation by rN-TcdB was also enhanced in the presence of Caco-2 lysates (Figures [5A,C](#F5){ref-type="fig"}). However, (H/K/N)Ras glucosylation by rN-TcdB was not observed even in the presence of lysates (Figures [5A,C](#F5){ref-type="fig"}).

![Enhanced glucosylation of substrate GTPases catalyzed by rN-TcdA and rN-TcdB in the presence of the Caco-2 lysates. GST-tagged GTPases (2 μM), UDP-\[^14^C\]glucose (40 μM) and recombinant rN-TcdA (3 nM, **A,B**) or rN-TcdB (0.3 nM, **A,C**) were incubated in the presence and the absence of Caco-2 lysates for the indicated times. Upon separation on SDS-PAGE, \[^14^C\]glucosylated GTPases were visualized by autoradiography. Signals were quantified using Kodak software and are given as mean ± SD of three experiments.](fmicb-09-03078-g005){#F5}

The recombinant glucosyltransferase domain of TcsL-6018 (rN-TcsL) preferably \[^14^C\]glucosylated GST-(H/K/N)Ras as compared with GST-Rac1 (Figure [6A](#F6){ref-type="fig"}), consistent with former observations ([@B16]). The latter observation apparently contradicts above observation that (H/K/N)Ras and Rac1 were glucosylated in TcsL-treated Caco-2 cells with almost comparable kinetics (Figure [1C](#F1){ref-type="fig"}). To solve this apparent contradiction, the glucosylation of either Rac1 and (H/K/N)Ras by rN-TcsL was analyzed in the presence of Caco-2 lysates. The glucosylation of Rac1 (Figures [6A,B](#F6){ref-type="fig"}) and H-Ras (Figures [6A,C](#F6){ref-type="fig"}) was strongly increased in the presence of Caco-2 lysates and Rac1 and (H/K/N)Ras were glucosylated with comparable kinetics (Figures [6A,D](#F6){ref-type="fig"}). Comparable glucosylation of Rac1 and (H/K/N)Ras by rN-TcsL was thus not observed until Caco-2 lysates were added to the cell-free system. A cell-free system complemented with Caco-2 lysates seems to be suitable for predicting intracellular glucosylation. In sum, substrate GTPase glucosylation by either rTcdA, rTcdB and rTcsL was enhanced in a cell-free system in the presence of lysates. Under these advanced conditions, (H/K/N)Ras was preferably glucosylated by rN-TcsL, to some extent by rN-TcdA, but not by rN-TcdB.

![Enhanced glucosylation of substrate GTPases catalyzed by rN-TcsL in the presence of the Caco-2 lysates. GST-tagged Rac1 **(A,B)** and GST-tagged Ras-GTPases **(A,C,D)** (2 μM), UDP-\[^14^C\]glucose (20 μM each) and recombinant rN-TcsL (0.3 nM) were incubated in the presence and the absence of Caco-2 lysates at 37°C for the indicated times. Upon separation on SDS-PAGE, \[^14^C\]glucosylated GTPases were visualized by autoradiography. Signals were quantified using Kodak software and are given as mean ± SD of three experiments.](fmicb-09-03078-g006){#F6}

Discussion
==========

Analysis of GTPase glucosylation by LCGT has widely been studied in cell-free systems to determine the specificities of LCGTs for particular small GTPases ([@B21]; [@B11]). Initial evaluation of the profiles of substrate GTPase profile of full-length TcdA-10463 and TcdB-10463 in cell-free systems has revealed that TcdA-10463 and TcdB-10463 specifically glucosylate the Rho subtype GTPases including RhoA, Rac1, and Cdc42 but not Ras subtype GTPases ([@B20],[@B21]). It had been assumed that similar specificity pattern exist in a cell-free and a cellular context. However, mass spectrometry-based analysis revealed that TcdA glucosylates RhoA/B/C, Rac1, RhoG, and Cdc42 but also the Ras subtype GTPases Rap1/2 and (H/K/N)Ras in Caco-2 cells (Figure [1](#F1){ref-type="fig"}) ([@B41]; [@B19]). The apparent contradiction that TcdA glucosylates Ras subtype GTPases in cellular but not in cell-free system is solved by advancing the cell-free system in two aspects: (1) Application of rN-TcdA: rN-TcdA better mimics the situation inside the cell, as the N-terminal glucosyltransferase domain of TcdA is cleaved off the delivery domain upon cell entry. rN-TcdA (applied at a relatively high concentration of 100 nM) has been shown to glucosylate a broader profile of substrate GTPases (including Ras subtype GTPases), while full-length TcdA fails to do so ([@B11]); (2) Complementation of the cell-free system with membrane-containing lysates: The substrate GTPases of the LCGTs are anchored to membranes through their C-terminally located polybasic domain and the isoprenyl residue. The 4-helix-bundle at the very N-terminus of the glucosyltransferase domain of the LCGTs mediates membrane anchoring as well ([@B38], [@B37]; [@B4]). Membrane anchoring of both substrate GTPases and the glucosyltransferase domain of the LCGTs facilitates enhanced glucosylation as compared with the soluble components, as substrate GTPase glucosylation catalyzed by either rN-TcdA (Figure [5B](#F5){ref-type="fig"}), rN-TcdB (Figure [5C](#F5){ref-type="fig"}), and rN-TcsL (Figure [6](#F6){ref-type="fig"}) was enhanced in a cell-free system upon addition of membrane-containing lysates. In particular, rN-TcdA-catalyzed glucosylation was strongly enhanced in the presence of Caco-2 lysate facilitating the detection of glucosylation of (H/K/N)Ras (Figures [5A,B](#F5){ref-type="fig"}).

(H/K/N)Ras is observed to be glucosylated in TcdA-treated Caco-2 cells, as evidenced by MRM analysis (Figure [1](#F1){ref-type="fig"}). In general, the LC-MS based MRM method exhibits a higher specificity but less sensitivity compared to the antibody detection. In terms of antibody detection, glucosylation of (H/K/N)Ras has been observed in TcdA-treated Caco-2 and Vero cells (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}), complementing the observations from the MRM analysis (Figures [1D,E](#F1){ref-type="fig"}). Ras glucosylation results in blocked Ras signaling in TcdA-treated cells, as evidenced in terms of inhibited Ras-ERK signaling (Figure [4](#F4){ref-type="fig"}). In contrast to TcdA, TcdB-10643-catalyzed glucosylation of Ras-GTPases was observed neither in Caco-2 cells (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) nor in Vero cells (Figure [3](#F3){ref-type="fig"}) nor in a cell-free system (Figure [5](#F5){ref-type="fig"}), as analyzed in terms of MRM analysis, immunoblot analysis, and \[^14^C\]glucosylation. Comparable to TcdB-10463, TcdB-R20291 did also not glucosylate Ras-GTPases in Caco-2 cells (Figure [1H](#F1){ref-type="fig"}). In conclusion, the two TcdB isoforms tested in this study (either of which derives from *C. difficile* toxinotype A+B+ strains) do not glucosylate Ras, which leads to the prediction that TcdB-10463 and TcdB-R20291 more efficiently promote inflammatory response in cells as compared to TcdA-10463. Finally, the GTPase profile of TcdB isoforms from so called variant, toxinotype A-B+ strains (such as strain 1470) remains to be analyzed because these strains must be expected to exhibit Ras glucosylation ([@B15]; [@B8]).

In TcsL-treated Caco-2 cells, Rac1 and (H/K/N)Ras exhibited almost comparable kinetics of glucosylation (Figure [1C](#F1){ref-type="fig"}). In a cell-free system, comparable glucosylation of Rac1 and (H/K/N)Ras by rN-TcsL was not observed until the cell-free system with complemented with membrane-containing lysates (Figure [6](#F6){ref-type="fig"}).

Upon combined treatment of Caco-2 cells with TcdA and TcdB, TcdA-catalyzed Ras glucosylation was suppressed (Figure [1F](#F1){ref-type="fig"}). This unexpected observation suggests that TcdB is capable of reducing TcdA uptake. TcdA enters target Caco-2 cells (but not other yet investigated cell lines) by clathrin-independent endocytosis, which requires intact actin dynamics ([@B32]; [@B28]; [@B3]). TcdB-induced glucosylation of Rho-GTPases results in actin depolymerization ([@B24]), which in turn might reduce TcdA uptake and subsequent Ras glucosyslation.

Taken together, the profiles of small GTPases glucosylated by LCGTs can be analyzed with the presented methods in cell-free systems, cultured cells, and in tissue from animal models and infected humans. The presented methods will allow the identification of new toxinotypes that exhibit different GTPase substrate profiles. Finally, observations from three independent experimental systems exclude that TcdB glucosylates Ras subtype GTPases. The observations of this study leads to the recommendation that TcdB (rather than TcdA) should be applied as tool in cell biology research to check for an involvement of Rho subtype GTPases in cellular processes.

Materials and Methods {#s1}
=====================

Materials
---------

Toxins: Recombinant toxins and toxin fragments as well as native toxin were used in parallel. The glucosyltransferase domains (covering amino acids 1--546) of TcsL (rN-TcsL, strain 6018) and TcdB (rN-TcdB, strain VPI10463) were expressed in *Escherichia coli* using the pGEX-2T vector system and affinity purified using Glutathion-Sepharose Beads (AP Biotech) as described ([@B14]). The glucosyltransferase domain (covering amino acid 1 to 1065) of TcdA (rN-TcdA, strain VPI10463) and full-length TcdA-10463, TcdB-10463, and TcdB-R20291 were expressed in the *Bacillus megaterium* expression system (MoBiTec, Germany) ([@B39]). Full length TcsL-6018 was produced in *C. sordellii* strain 6018 and purified yielding only one band on SDS-PAGE as previously described ([@B13]). In brief, a dialysis bag containing 900 mL of 0.9% NaCl in a total volume of 4 liters of brain heart infusion (Difco, BD Life Sciences, Heidelberg, Germany) was inoculated with 100 mL of an overnight culture of *C. sordellii*. The culture was grown under microaerophilic conditions at 37°C for 72 h. Bacteria were removed from the dialysis bag solution by centrifugation. Proteins from the culture supernatant were precipitated by ammonium sulfate at 70% saturation. The precipitated proteins were dissolved in 50 mM Tris-HCl, pH 7.5 buffer and extensively dialyzed against 50 mM Tris-HCl, pH 7.5 buffer for 24 h. The protein solution was loaded onto an anion exchange column (MonoQ, AP Biotech, New Jersey, NJ, United States). TcdA was eluted with 50 mM Tris-HCl, pH 7.5, at 150--200 mM NaCl. TcsL or TcdB were eluted at 500--600 mM NaCl. The toxins were subsequently dialyzed against buffer (50 mM Tris-HCl pH 7.5, 15 mM NaCl). Immunoblot analyses were used to identify and calculate the amount of isolated toxins.

Purification of recombinant proteins: GST-tagged Rho and Ras subtype GTPases were expressed in *E. coli* using the pGEX-2T vector system and affinity purified using Glutathion-Sepharose Beads (AP Biotech) as described ([@B14]).

Cell Culture and Preparation of Lysates
---------------------------------------

African green monkey kidney (Vero) cells and human epithelial colorectal adenocarcinoma (Caco-2) cells were cultivated in Dulbecco's modified Eagle Medium (DMEM) containing 10% fetal calf serum (FCS), 100 U/ml penicillin G and 100 μg/ml streptomycin in a humidified atmosphere containing 5% CO~2~. Cells sub-confluently seeded in 3.5-cm dishes were treated with TcdA, TcdB, and TcsL according to the indicated concentrations. Upon incubation time, the cells were rinsed with 5 ml of ice-cold phosphate-buffered saline and scraped off in 200 μl of Laemmli lysis buffer per dish. The cells were disrupted mechanically by sonification (five times on ice). The lysate were submitted to immunoblot analysis. For MRM analyses cells were washed at least three times with ice-cold phosphate buffered saline and solubilized in Tris-HCl buffer, pH 7,5 containing 20 mM NaCl and 1 mM DTT homogenized by sonification and centrifuged at 13,000 ×*g* to remove cell debris. Protein levels were determined by the method of Bradford. Crude extracts were stored at -20°C.

Immunoblot Analysis
-------------------

Cell lysates were separated on 15% polyacrylamide gels and transferred onto nitrocellulose for 2 h at 250 mA, followed by blocking with 5% (w/v) nonfat dried milk for 1 h. Blots were incubated with the appropriate primary antibody with dilution according to the manufacturers' instructions \[beta-actin(Mab AC-40, Sigma; dilution 1:5000); PAK2 (Cell signaling 2608, dilution 1:1000); phospho-S144/141-PAK1/2 (Abcam ab40795; dilution 1:2000); Rac1 (BD Transduction Laboratories 610650, clone 102; dilution 1:1000); Rac1(Millipore 05-389, clone 23A8; dilution 1:1000); Ras(Mab27H5, Cell Signaling 3339, dilution 1:200); H-Ras (C20, SantaCruz sc-520, dilution 1:200); in buffer B (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5 mM KCl, 0.05% (w/v) Tween 20\] for 18 h and subsequently for 2 h with a horseradish peroxidase-conjugated secondary antibody (mouse: Rockland 610-1034-121; dilution 1:3000; rabbit Rockland 611-1302; dilution 1:3000). For the chemiluminescence reaction, ECL Femto (Pierce) was used. The signals were analyzed densitometrically using the KODAK 1D software.

Preparation of Caco-2 Cell Lysates
----------------------------------

Caco-2 cells were disrupted mechanically by sonification on ice in a detergent-free lysis buffer containing 10 mM Tris/HCl (pH 7.4), 10 mM NaCl, 2 mM MgCl2, and EDTA-free protease inhibitor cocktail (Roche, Berlin, Germany). Crude cell lysates were centrifugated at 1,000 ×*g* at 4°C for 10 min to remove the nuclear fraction and intact cells. The supernatant was used as "lysate."

Glucosyltransferase Reaction
----------------------------

Recombinant Rho and Ras subtype GTPases (50 μg/mL) was incubated with either rN-TcdA, rN-TcsL or rN-TcdB in glucosylation buffer (50 mM of HEPES pH 7.4, 0.1 mM ⋅ MgCl2, 150 mM ⋅ KCl, 100 μg/mL of BSA, 20 μM of UDP-\[^14^C\]glucose) (Biotrend, Cologne, Germany) in a total volume of 20 μL at 37°C for the indicated times. Proteins were analyzed by 12.5% SDS-PAGE, and \[14C\]glucosylated Rho and Ras subtype GTPases were visualized by Phosphorimaging (Cyclone, PerkinElmer Life and Analytical Sciences, Shelton, United States).

MRM Analysis
------------

Multiple reaction monitoring analysis was conducted for determining glucosylation extent of small GTPases as previously described ([@B19]). Briefly, proteins were separated by SDS-PAGE and area between 15 and 25 kDa was cut. Proteins were digested using trypsin and peptides were subjected to MRM analysis using a triple quadrupol mass spectrometer (QTRAP4000, SCIEX). Peptides were separated in a nano LC system using an Acclaim PepMap C18 column (Thermo Fisher Scientific) that was directly connected to the ion source of the mass spectrometer. For quantification acquired raw data were processed with the Skyline software (MacCoss Lab Software, Canada) ([@B23]).
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